Anti-IL-5/5Ra biologics improve work productivity and activity in severe asthma: a RAPSODI registry-based cohort study

References

• Available from: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf [last accessed 1 March 2020].
   Google Scholar
• Gruffydd-Jones K, Thomas M, Roman-Rodríguez M, Infantino A, FitzGerald JM, Pavord I, Haddon JM, Elsasser U, Vogelberg C. Asthma impacts on workplace productivity in employed patients who are symptomatic despite background therapy: a multinational survey. J Asthma Allerg. 2019;12:183–194. doi:10.2147/JAA.S204278.
   PubMed Web of Science ®Google Scholar
• Lee LK, Ramakrishnan K, Safioti G, Ariely R, Schatz M. Asthma control is associated with economic outcomes, work productivity and health-related quality of life in patients with asthma. BMJ Open Respir Res. 2020;7(1):e000534. doi:10.1136/bmjresp-2019-000534.
   PubMed Web of Science ®Google Scholar
• Soong W, Chipps BE, O’Quinn S, Trevor J, Carr WW, Belton L, Trudo F, Ambrose CS. Health-related quality of life and productivity among US patients with severe asthma. J Asthma Allerg. 2021;14:713–725. doi:10.2147/JAA.S305513.
   PubMed Web of Science ®Google Scholar
• Satuf C, Monteiro S, Pereira H, Esgalhado G, Afonso RM, Loureiro M. The protective effect of job satisfaction in health, happiness, well-being and self-esteem. Int J Occup Saf Ergon. 2018;24(2):181–189. doi:10.1080/10803548.2016.1216365.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Prazma CM, Chupp GL, Bradford ES, Forshag M, Mallett SA, Yancey SW, Smith SG, Bel EH. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions. Respir Res. 2021;22(1):171. doi:10.1186/s12931-021-01746-4.
   PubMed Web of Science ®Google Scholar
• Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023–1042. doi:10.1111/all.14221.
   PubMed Web of Science ®Google Scholar
• Albers FC, Bratton DJ, Gunsoy NB, Cockle SM, Alfonso-Cristancho R, Braunstahl GJ. Mepolizumab improves work productivity, activity limitation, symptoms, and rescue medication use in severe eosinophilic asthma. Clin Respir J. 2022;16(3):252–258. doi:10.1111/crj.13474.
   PubMed Web of Science ®Google Scholar
• Eger K, Kroes JA, ten Brinke A, Bel EH. Long-term therapy response to anti-IL-5 biologics in severe asthma—A real-life evaluation. J Allergy Clin Immunol Pract. 2021;9(3):1194–1200. doi:10.1016/j.jaip.2020.10.010.
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Kroes JA, Eger KA, Mau Asam PF, Hofstee HB, Bendien SA, Braunstahl GJ, Broeders MEAC, Imming LM, Langeveld B, RAPSODI team, et al. Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma – First initiators and switchers. J Allergy Clin Immunol Pract. 2022;10(8):2099–2108.e6. doi:10.1016/j.jaip.2022.04.014.
   PubMed Web of Science ®Google Scholar
• Korn S, Both J, Jung M, Hubner M, Taube C, Buhl R. Prospective evaluation of current asthma control using ACQ6 and ACT compared with GINA criteria. Ann Allergy Asthma Immunol. 2011;107(6):474–479.
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47(2):76–83.
   PubMed Web of Science ®Google Scholar
• Chen H, Blanc PD, Chawla A, Hayden M, Bleecker ER, Lee JH. Assessing productivity impairment in patients with severe or difficult-to-treat asthma: validation of the work productivity activity impairment – Asthma Questionnaire. J Allergy Clin Immunol. 2006;117(2):S181.
   Web of Science ®Google Scholar
• Meetinstrumentenzorg. Available from: https://meetinstrumentenzorg.nl/instrumenten/work-productivity-and-activity-impairment-questionnair [last accessed 7 November 2022.].
   Google Scholar
• Bonini M, Di Paolo M, Bagnasco D, Baiardini I, Braido F, Caminati M, Carpagnano E, Contoli M, Corsico A, Del Giacco S, et al. Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur. Respir Rev. 2020;29:190137.
   PubMed Web of Science ®Google Scholar
• Kon SSC, Canavan JL, Jones SE, Noalan CM, Clark AL, Dickson MJ, Haselden BM, Polkey M, Man WD-C. Minimum clinically important difference for COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2:195–203.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400.
   PubMed Web of Science ®Google Scholar
• Behrens F, Tony HP, Koehm M, Schwaneck EC, Gnann H, Grerer G, Burkhardt H, Schmalzing M. Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study. Clin Rheumatol. 2020;39(9):2583–2592.
   PubMed Web of Science ®Google Scholar
• Ariëns LFM, Bakker DS, Spekhorst LS, Van der Schaft J, Thijs JL, Haeck I, Flinterman AE, Kamsteeg M, Schuttelaar MLA, De Bruin-Weller MS. Rapid and sustained effect of dupilumab on work productivity in patients with difficult-to-treat atopic dermatitis: results from the Dutch BioDay registry. Acta Derm Venereol. 2021;101(10):adv00573. doi:10.2340/00015555-3886.
   PubMedGoogle Scholar
• Wu JJ, Lin C, Sun L, Goldblum O, Zbrozek A, Berge R, Augustin M, Feldman SR. Minimal clinically important difference (MCID) for work productivity and ­activity impairment(WPIA) questionnaire in psoriasis patients. J Eur Acad Dermatol Venereal. 2019;33(2):318–324.
   PubMed Web of Science ®Google Scholar
• Meting IVRPH-indicatoren 2020. Available from: https://www.cbs.nl/nl-nl/maatwerk/2022/09/meting-ivrph-indicatoren-2020 [last accessed 12 September 2022].
   Google Scholar
• Sadatsafavi M, Rousseau R, Chen W, Zhang W, Lynd L, FitzGerald JM. The preventable burden of productivity loss due to suboptimal asthma control: a population-based study. Chest. 2014;145(4):787–793.
   PubMed Web of Science ®Google Scholar
• Zazzali JL, Raimundo KP, Trzaskoma B, Rosén KE, Schatz M. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results. Allergy Asthma Proc. 2015;36(4):283–292.
   PubMed Web of Science ®Google Scholar
• Hiles SA, Harvey ES, McDonald WM, Peters M, Bardin P, Reynolds PN, Upham JW, Baraket M, Bhikoo Z, Bowden J, et al. Working while unwell: workplace impairment in people with severe asthma. Clin Exp Allergy. 2018;48(6):650–662.
   PubMed Web of Science ®Google Scholar